(4R)-N-benzyl-N-methyl-4-[(3R,7R,9S,10S,12S,13R,14S,17R)-3,7,12-tris(3-aminopropoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentan-1-amine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (4R)-N-benzyl-N-methyl-4-[(3R,7R,9S,10S,12S,13R,14S,17R)-3,7,12-tris(3-aminopropoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentan-1-amine
• 化学式: C₄₁H₇₂N₄O₃
• 分子量: 669.0
• InChiKey: OHGFUPQFFRJXNJ-XYCGPNBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  48
• 可旋转键数：
  19
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Method of Treating Ciliated Tissue Using CSA Micelles
  申请人：Genberg Carl

  公开号：US20210361672A1

  公开（公告）日：2021-11-25

  The present disclosure describes compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. A treatment composition comprises a CSA compound, a poloxamer, and a carrier. The combination of CSA compound and poloxamer allows higher concentrations of CSA compound to be used. Where such doses would normally disrupt ciliary function, the poloxamer prevents damage to ciliated tissue without inhibiting the antimicrobial effectiveness of the CSA compound.